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Purpose
The purpose of this study was to compare medication adherence rates and type 2 diabetes mellitus (T2DM) health outcomes in a sample of underserved patients with suboptimally controlled T2DM (A1C >7%) who had received pharmacist-directed medication therapy management (MTM) to those who had not received MTM.
Methods
A retrospective review of 100 patient records was conducted. For the MTM group, a pharmacist engaged patients in patient-centered services to optimize therapeutic outcomes. Non-MTM patients received usual care. Outcomes were A1C, medication adherence, blood pressure, lipids, and creatinine. Group comparisons on clinical outcomes were analyzed before and after matching MTM and non-MTM patients on demographic characteristics.
Introduction
Underserved populations are at increased risk for type 2 diabetes mellitus (T2DM) and other chronic health conditions. 1, 2 These vulnerable communities include persons who are underinsured/uninsured and of lower socioeconomic status. 1, 3 Among individuals with T2DM, glycemic control is worse in the uninsured than the insured. 4 Low-income populations are also more likely to experience T2DM-related health complications and early mortality than middle-income and high-income populations. 2, 5 Ethnoracial minorities, in particular African Americans and Hispanics, are also disproportionately affected by T2DM 6 and make up a large portion of these at-risk communities. 7 Adherence to an anti-diabetes medication regimen is a major determinant of glycemic control 8 and T2DM-related health outcomes, 9, 10 yet many patients with chronic health conditions experience difficulty adhering to their medication regimen. 11 Finding an effective strategy to improve treatment adherence may help to address socioeconomic and racial disparities in T2DM disease outcomes.
There is an emerging initiative to discover effective ways to improve self-care behavior and T2DM health outcomes through interdisciplinary care teams. Pharmacist intervention models have shown promise as an effective strategy to manage T2DM and improve adherence to antidiabetes medications. 12 Medication therapy management (MTM), 13 a range of patient-centered services tailored to a patient's needs provided by a pharmacist to optimize therapeutic outcomes, may be particularly useful in improving adherence to medication regimens and subsequent health outcomes. In order to determine the effectiveness of MTM intervention in a community health center, we compared medication adherence rates (i.e., prescription refills) between individuals with T2DM who received pharmacist-directed MTM compared to those who had not received MTM. This study also examined group differences in T2DM-related health outcomes (A1C, blood pressure, lipids, and renal function). In order to control for confounding demographic factors, a second analysis was conducted after matching MTM and non-MTM patients on demographic characteristics (age, gender, race, and ethnicity). The study hypothesis was that MTM would be associated with lower A1C levels and better medication adherence. This study adds to the existing literature by examining how enhanced pharmacy care relates to T2DM medication adherence and health outcomes in underserved communities. Findings from this study may inform the development of metrics to more systematically assess the effects of pharmacist-directed MTM on health outcomes.
Methods

Design and Collaborative Team
This study used a retrospective case-control design and was the product of a community-academic partnership. Retrospective case-control designs leverage existing data sources and are often implemented to generate hypotheses for future prospective research. Limitations of this type of design include dependence on existing documentation and causality cannot be determined. Key team members from the community partner organization, a community health center, included a clinical pharmacist and pharmacy personnel. The community partners provided expertise in MTM, identified patients for the study, abstracted data from medical records, obtained prescription refill data, and participated in the interpretation of the data and dissemination of the findings. The community partners received training in data collection and management from the academic partners. The academic partners also provided expertise in clinical and comparative effectiveness research, performed statistical analyses, and assisted with data interpretation and dissemination of study findings. Both the academic and community partners participated in the creation of data collection tools. This study was approved by the Vanderbilt University Institutional Review Board.
Study Population
Patients from a community health clinic who were 18 years or older were identified through administrative medical record review using International Classification of Diseases (ICD-9) codes for T2DM (250.00, 250.02) and T2DM with disease complications (250.40, 250.42, 250.50, 250.52, 250.60, 250.62, 250.80, 250.82). Suboptimal control was defined as having at least one documented A1C value >7%, which is the benchmark for glycemic control 14 and a risk factor for disease-related microvascular complications. 15 Patients in the non-MTM (control) group had no contact with the clinical pharmacist. Patients in the MTM group were referred to the pharmacist for MTM by their primary care provider (PCP) and had clinical data from at least 3 clinic visits during a consecutive 12-month period following the first MTM visit. Patients in this group were identified from medical record documentation noting contact with the clinical pharmacist and recorded information describing any instruction provided for optimizing therapeutic outcomes of anti-diabetes medication and T2DM disease management. Demographic variables (age, gender, race, and ethnicity) were used to select non-MTM patients. Patient record data were collected from clinic visits that occurred between the years of 2011 and 2013. A figure illustrating patient record selection is provided in Figure 1 . 
Measures Clinical Outcomes
Clinical outcomes of interest included glycemic control (A1C), blood pressure, lipids (high-density lipoprotein [HDL] and low-density lipoprotein [LDL]), triglycerides, creatinine levels, and medication adherence. Medication adherence was determined by anti-diabetes prescription refill. Pharmacy personnel contacted retail pharmacies by phone to query patient prescription refill status. Refill percentage data were calculated from the ratio of the number of anti-diabetes medication refills dispense (from pharmacy record) to the number of medication refills prescribed. Patients were identified as adherent if they met their prescription refill a minimum of 85% of the time. Prescription refill is a common outcome measure in diabetes medication adherence research. 16, 17 Prescription refill data derived from pharmacy records circumvent issues of patient recall and social desirability bias. A caveat of refill data is that medication adherence cannot be assumed nor does refill data provide details on patient dosing errors. For patients in the MTM group, prescription refill information was captured for a year post initial MTM consultation. For patients in the non-MTM group, prescription refill information was also captured for a year.
Intervention Medication Therapy Management
Medication therapy management refers to a group of analytical, educational, and monitoring services provided by the pharmacist to optimize therapeutic outcomes for the patient. 13 For this study, the pharmacist used a patientcustomized, semi-structured approach. The pharmacist reviewed the patient's T2DM medication regimen and provided verbal education and training on medication delivery and best administration sites and education on health-promoting behaviors (diet, exercise, smoking cessation). Patients were asked to "teach back" the information to confirm understanding. Frequency and duration data on MTM were not collected.
Statistical Analyses
Mann-Whitney tests for nonparametric data 2-group comparisons were employed due to violations of normality in continuous dependent variables. For the first analysis, group differences in dependent variables were compared between the MTM group and non-MTM group. For the second analysis, a case-control design was used to match a subgroup of patients using demographic data. Patients were matched on key demographic factors including age (±5 years), gender, race, ethnicity, and body mass index (BMI) (±3 kg/m 2 ). The matched subsample included 58 patients. Pearson chi-square test was used to determine group differences in categorical dependent variables. Sample size and power calculations were performed using data from a published study of MTM and diabetes, which had a difference in mean A1C between the matched pairs of 0.8% and a standard deviation of 2%. 18 Using this mean for a study with 50 pairs of patients, we calculated that this sample size will provide of a power of 80% and a type 1 error rate of 0.05. Significance level was set a priori at P < .05. SPSS version 22 (SPSS, Inc, Chicago, Illinois, USA) was used to analyze the data.
Results
Patient characteristics by group status before and after matching are provided in Table 1 . Patients in this study ranged in age from 24 to 77 years old (M = 53.7 years, SD = 12.5) and were predominately female (58%). Prior to matching, patients in the MTM group were older (P < .01) and had a higher body mass index, although the difference was not statistically significant (P = .05) compared to the non-MTM group.
Medication Adherence
Prior to matching, medication adherence rates differed between the 2 groups. Results showed 64.6% of patients in the MTM group were medication adherent compared to 10% of patients in the non-MTM group, χ 2 (1) = 27.13, P < .001. After matching, these findings persisted, with more patients in the MTM group (62%) being medication adherent than in the non-MTM group (7%), χ 2 (1) = 18.51, P < .001. Additional details are provided in Table 2 .
Clinical Outcomes
Prior to matching, a significant difference in glycemic control between the MTM and non-MTM group was observed. Patients in the MTM group (M rank = 27.62, n = 50) had lower A1C levels than patients in the non-MTM group (M rank = 73.38, n = 50), z(160) = -7.89, P < .0001. Significant differences in LDL levels were also observed. Patients in the MTM group (M rank = 40.80, n = 50) had lower LDL levels than patients in the non-MTM group (M rank = 53.00, n = 50), z(774.0) = -2.18, P = .02. There was no significant difference in blood pressure, HDL, triglycerides, or creatinine between the groups. After matching, a significant difference in glycemic control remained, with the MTM group having lower A1C levels than the non-MTM group (P < .001). After matching, the groups did not differ on any other clinical outcomes (all P values > .05). Group means and standard deviations are presented in Table 2 .
Discussion
This study found pharmacist-directed MTM in a community health center was associated with better medication adherence and lower A1C compared to patients who did not receive MTM. These findings are aligned with previous reports demonstrating a positive association between pharmacy interventions and improved T2DM medication adherence. 8, 12, 19 This study's results differ from that of Odegard and colleagues, 20 who reported no effect of a 6-month pharmacist intervention on T2DM medication adherence. Differences in study findings may be attributed to differences in how medication adherence was defined. Participants in the two studies may also have experienced different barriers related to medication adherence. It is important to note, among published studies examining the association between pharmacist interventions and T2DM medication adherence, definitions of adherence vary widely (eg, self-report, prescription refill, proxy reports), and this may pose a challenge in harmonizing findings from this growing area of research. Therefore, future work is needed to develop a systematic definition of medication adherence. Nevertheless, these results do suggest enhanced pharmacy care is a potentially valuable tool to increase medication adherence in individuals with T2DM. Glycemic control is strongly associated with medication adherence 21 ; therefore, results in this study are expected. Prior to matching, cholesterol levels in this study were also lower in the MTM group than the non-MTM group. These results are similar to other reports demonstrating a favorable association between pharmacy care and health indices associated with T2DM. [22] [23] [24] The current study enhances the existing literature in several important ways. First, this study collected information on medication adherence and modifiable markers of T2DM that are responsive to MTM in a high-risk, vulnerable population, often underrepresented in clinical research. Second, implementation of this study in a community health center setting sheds light on the potential benefits of MTM as an effective tool to treat chronic disease and address ethnoracial and socioeconomic health disparities. Third, the design of this study may serve as a model for community and academic institutional partnerships for the implementation of community-based research studies. Through a collaborative process, both partners participated in the pre-implementation and execution of this study. Results from this study advanced both partners' understanding of community health and the role of pharmacy care. Finally, preliminary data from this study will set the foundation for developing a standardized MTM data recording tool that can be used in diverse health care settings. This tool will allow for the replication of our study findings and a more rigorous examination of effective MTM strategies to increase medication adherence and improve disease outcomes.
There are limitations to this study that should be highlighted. Findings may not be generalizable because of the small sample number of patient health records utilized in this study. Information on the number of clinic visit was not collected in this study. It is possible study findings may be in part related to group differences in the number of clinic visits. The retrospective case-control cohort design used in this study can only determine associations between participation in the MTM intervention, medication adherence, and T2DM outcomes. An alternative quasiexperimental study design to the one implemented in the current study is a pre-post study design. However, this design could not be implemented due to logistical restraints associated with obtaining patient data. A prospective randomized control design is needed to determine whether MTM has a positive causal effect on medication adherence and T2DM health outcomes. Finally, the MTM model used in this study was semi-structured and derived from medical record documentation.
Implications for Practice
Pharmacists are uniquely and ideally positioned to provide patient education, counseling on medication and disease, and information about health-related community resources and encourage health-promoting behavior. 23 These skills in a community health center, where vulnerable populations often receive care, may be particularly valuable in improving health outcomes for high-risk populations. The results of this study show that a pharmacistdirected MTM is positively associated with medication adherence and disease outcomes in patients with suboptimally controlled T2DM. These findings in a community health clinic population have broad implications for improving health care delivery and health outcomes in community-based settings. Underserved populations are vulnerable to T2DM and other chronic conditions; furthermore, their limited access to recommended health care likely makes this segment of the population the most in need of supportive chronic disease management services.
